Status:
UNKNOWN
Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy
Lead Sponsor:
Kobe University
Collaborating Sponsors:
Japan Medical Association
Nobelpharma
Conditions:
Muscular Dystrophy, Duchenne
Eligibility:
MALE
4+ years
Phase:
PHASE2
Brief Summary
Duchenne Muscular Dystrophy (DMD) is inherited neuromuscular disorders due to mutation in the gene that encodes critical muscle protein called dystrophin. Currently, there is no effective treatment op...
Eligibility Criteria
Inclusion
- Diagnosis of DMD resulting from a nonsense mutation by whole genome sequencing of the dystrophin gene
- To have intact right or left biceps muscles, or an alternative muscle group that is able to be underwent for appropriate evaluation of efficacy
- To meet the following criteria at screening (baseline visit), within 30 days prior to the first dose of study drug
- Ambulant and able to walk at least 75 meters during the 6MWT
- Able to comply with and complete all protocol requirements, and judged by the investigator to be appropriate to participate in the study from the screening results
- Aged at least 4 years at the time of giving informed consent
- Male
- Able to be hospitalized for the study requirement
- Signed Informed consent by parents/legal guardian and/or signed assent by the subject (age of assent to be determined by IRB)
Exclusion
- Prior exposure to investigational medicines that have a potential of restoring dystrophin or other functional protein (readthrough, exon skipping, utrophin upregulation therapy etc.)
- Known mutation at nucleotide 1555 in 12S rRNA gene of mitochondrial DNA, and/or personally or families have been treated or have a history of eight cranial nerve disorder （hearing loss、vertigo、tinnitus etc.）as a result of aminoglycoside use
- Inability to hear within the range of 0 to 25 dB by pure tone audiometry, abnormalities on auditory brainstem response audiometry, and/or loss of frequency by distortion product oto acoustic emissions at screening
- Poor oral intake or enable to oral intake, and/or bad general status
- Known allergies to NPC-14, other aminoglycosides, and/or bacitracin
- Presence of anti-dystrophin antibody at the baseline assessments
- Cys-C ≥1.2 mg/L and/or creatinine concentration \>1.5 times the upper limit of age corrected normal range
- Left ventricular ejection fraction (EF) \<40% or left ventricular fractional shortening (FS) \<25%, and/or ≥480 msec QTc (corrected QT interval by Fridericia's method)
- Need of mechanical ventilation
- Forced vital capacity (FVC) \<50% predicted
- Clinically significant concomitant diseases (hematology, psychoneurotic, hepatic, pulmonary, endocrine, immune, renal, and gastroenterological diseases), and/or cancer
- Impairment of intellectual functions, and/or expressive language ability which might interfere with study assessments
- Treatment with other systemic aminoglycoside within 6 months prior to the first administration of study drug
- Initiation of systemic glucocorticosteroids treatment, and/or start exercise cure, physical therapy, or occupational therapy which might interfere with study assessments. Changing of dose and schedule of systemic glucocorticosteroids within 6 months prior to the first administration of study drug
- History of any surgical procedure within months prior to the first administration of study drug or have a plan during study
- History of sever allergy from food and medicine like an anaphylaxis shock or generalized rash
- Participation in any other clinical trial and intake of any investigational drug within 6month of study entry
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2015
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT01918384
Start Date
August 1 2013
End Date
October 1 2015
Last Update
September 3 2015
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Kobe university hospital, department of pediatrics
Kobe, Hyōgo, Japan, 650-0017
2
Hyogo College of Medicine
Nishinomiya, Hyōgo, Japan, 663-8501
3
National center of neurology and psychiatry
Kodaira, Tokyo, Japan, 187-8551
4
Tokyo Women's Medical University
Shinjuku-ku, Tokyo, Japan, 162-8666